INTRAVENOUS METHYLPREDNISOLONE EFFECTS ON RECTUS MUSCLES IN THYROID EYE DISEASE
Article Sidebar
-
Thyroid Eye Disease, Extraocular Muscle, Intravenous Methylprednisolone Therapy
Abstract
Introduction & Objective:
Intravenous methylprednisolone has been used in management of Thyroid Eye Diseases (TED) which was an autoimmune inflammatory disease of the orbital tissues and the eyes. Previous study has shown benefits of intravenous methylprednisolone therapy on TED but there was need of quantitative measure to assess the effect of intravenous methylprednisolone therapy on extraocular rectus muscles. This study aimed to report the effect of high-dose intravenous methylprednisolone pulse therapy on inferior, medial, superior, and lateral rectus muscles and providing data distribution of active TED before and after therapy.
Methods:
Retrospective analyses were used in the data collection of patients with active Thyroid Eye Disease (TED) underwent high-dose intravenous methylprednisolone pulse therapy regiment 500mg every week for six consecutive weeks at Sardjito Eye Centre between January 2022 and December 2022. Ophthalmological investigation and quantitative computed tomography (CT) scan of the orbit were performed before and after methylprednisolone pulse therapy and demographics data were presented in tables and graphs.
Results:
This study included 62 eyes of 31 patients (61,3% female) with mean age of 37.8±13.47 years old. The mean thickness of Superior Rectus (SR) muscle before therapy were 4.12±2.20 mm and significantly decreased to 3.70±1.54 mm post therapy. There was no significant difference in delta mean Inferior Rectus (?IR) -0.18±1.69 (p=0.381), Medial Rectus (?MR) -0.34±1.68 (p=0.116), and Lateral Rectus (?LR) -0.33±1.94 (p=0.188)
Conclusion:
The treatment of Thyroid Eye Disease (TED) with high dose intravenous corticosteroid is safe and effective in reducing extraocular muscle tissue thickness with minimal side effects.
Keywords:
Thyroid Eye Disease, Extraocular Muscle, Intravenous Methylprednisolone Therapy.
Full text article
References
Men CJ, Kossler AL, Wester ST. Updates on the understanding and management of thyroid eye disease. Ther Adv Ophthalmol. 2021 Jun 30; 13: 25158414211027760.doi:10.1177/25158414211027760. PMID: 34263138; PMCID: PMC8252358.
Shah SS, Patel BC. Thyroid Eye Disease. [Updated 2022 May 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/ NBK582134/
Tambe K, Bhargava J, Tripathi A, Gregory M, Burns J, Sampath R. The role of intravenous methylprednisolone immunosuppression in the management of active thyroid eye disease. Orbit. 2010 Oct;29(5):227-31. doi: 10.3109/01676831003660663. Epub 2010 Sep 2. PMID: 20812826
Yang DD, Gonzalez MO, Durairaj VD. Medical management of thyroid eye disease. Saudi J Ophthalmol. 2011;25(1):3-13. doi: 10.1016/j.sjopt.2010.10.001
Salvi M, Vannucchi G, Campi I, Curro N, Dazzi, D, & Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P. Treatment of graves' disease and associated opthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open study. European journal of endocrinology / European Federation of Endocrine Societies. 2007. 156. 33-40. 10.1530/eje.1.02325.
McAlinden C. An overview of thyroid eye disease. Eye Vis (Lond). 2014 Dec 10; 1:9. doi: 10.1186/s40662-014-0009-8. PMID: 26605355; PMCID: PMC4655452.
Chandra P, Sudhalkar A, Jalali S, Pesala V, Narayanan R, Sahu C, Chhablani J. Echographic study of extraocular muscle thickness in normal Indian population. Saudi J Ophthalmol. 2014 Oct;28(4):281-6. doi: 10.1016/j.sjopt.2014.05.003. Epub 2014 Jun 6. PMID: 25473344; PMCID: PMC4250497.
Mohammed Jeelani, RH Taklikar, Anupama Taklikar, Vijayanath Itagi, Amruta Bennal. Variation of intraocular pressure with age and gender. Natl J Physiol Pharm Pharmacol. 2014; 4(1): 57-60. doi:10.5455/njppp.2014.4.040720132
Liu X, Pan X, Ma Y, Jin C, Wang B, Ning Y. Variation in intraocular pressure by sex, age, and geographic location in China: A nationwide study of 284,937 adults. Front Endocrinol (Lausanne). 2022; 13:949827. Published 2022 Aug 25. doi:10.3389/fendo.2022.949827
Young SM, Lim AYN, Lang SS, Lee KO, Sundar G. Efficacy, and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease. Orbit. 2019 Oct;38(5):362-369. doi: 10.1080/01676830.2018.1553189. Epub 2018 Dec 12. PMID: 30540214.
Rashad, R.; Pinto, R.; Li, E.; Sohrab, M.; Distefano, A.G. Thyroid Eye Disease. Life 2022, 12, 2084. https://doi.org/10.3390/ life12122084
Strianese D. Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S Suppl 1): S56-S59. doi:10.1097/IOP.0000000000001131
Higashiyama T, Nishida Y, Ohji M. Relationship between magnetic resonance imaging signal intensity and volume of extraocular muscles in thyroid-associated ophthalmopathy with methylprednisolone pulse therapy. Clin Ophthalmol. 2016; 10:721-729
https://doi.org/10.2147/OPTH.S105096
Liu X, Wang S, Qin L, et al. Short and long-term effects of high-dose intravenous methylprednisolone pulse therapy on thyroid-associated ophthalmopathy. Exp Ther Med. 2016;12(2):901-908. doi:10.3892/etm.2016.3446
Singh, M. Role of Intravenous Methylprednisolone in Moderate to Severe Thyroid Associated Orbitopathy (Tao) in Indians: A Tertiary Care Institute Study. Medical & Surgical Ophthalmology Research (2018): n. pag.
Authors
Copyright (c) 2024 Milzan Murtadha, Agus Supartoto, Purjanto Tepo Utomo, Banu Aji Dibyasakti, Irene Titin Darajati
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.